| Item | Medicine |
|---|---|
| Brand name | Daklinza/Sunvepra |
| Generic name | Daclatasvir/Asunaprevir |
| Final report date | 03/27/2019 |
| Target population (1) | Chronic hepatitis C GT1(Y93/L31 wildtype) |
| Comparator | Only follow-up (no treatment) |
| ICER | Less than JPY 5 million/QALY |
| Target population (2) | Compensated cirrhosis C GT1(Y93/L31 wildtype) |
| Comparator | Only follow-up (no treatment) |
| ICER | Less than JPY 5 million/QALY |
Daclatasvir and Asunaprevir (Daklinza and Sunvepra)